Is Portage Biotech Inc (PRTG) Stock About to Get Hot Monday?

Portage Biotech Inc (PRTG) stock has fallen 11.02% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Portage Biotech Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTG!

See Full PRTG Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PRTG Stock Today?

Portage Biotech Inc (PRTG) stock is unchanged 0% while the S&P 500 has fallen -0.18% as of 10:37 AM on Monday, Oct 2. PRTG is unmoved $0.00 from the previous closing price of $2.10 on volume of 30,109 shares. Over the past year the S&P 500 has gained 16.37% while PRTG has fallen -72.11%. PRTG lost -$6.28 per share in the over the last 12 months.

More About Portage Biotech Inc

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Click Here to get the full Stock Report for Portage Biotech Inc stock.